I recently met with a company called Delcath, which has a procedure designed to combat metastases to the liver. It works by infusing high doses of chemotherapy directly int...

The FDA is launching a new program in which they will consider and incorporate the patient perspective into drug development.  They will choose 20 diseases for the pro...

We are in the middle of another election cycle and much of the conversation is on how much money is being spent on campaigns.  In this context, a recent blog by Leif V...

 Years ago I heard a song by Harry Chapin:  “If a man tried to take his time on Earth, and prove before he died what one man's life could be worth, well...

We live in an information age.  The lyrics of a long-forgotten song, the email address of a high school sweetheart, the cube root of 97 are all available in microsecon...

His wife died of melanoma a few months ago and he was talking about hope. I can’t claim to have known her well, but in my own encounters with her and by all accounts,...

  The answers came back fairly quickly:  “Yes,” “Yes,” “Happy to participate,” “Glad to help,”    We are...

Today we heard that drivers in the United States have more skin cancer on their left arm than on their right.  This news came just after a big media push from the FDA ...

I had dinner last night with two melanoma researchers.  One is an M.D.; the other has an M.D and a Ph.D.  The discussion quickly moved to new studies and treatmen...

The melanoma community has waited a long time for a breakthrough. See what MRF and patients have had to say about the FDA's decision on Yervoy:   F.D.A. Approves D...

The news is not a surprise.  We have been waiting for it for days.  Maybe years.  I was sitting in my office this morning when the phone rang.  On the l...

Pharmawire recently featured this article on the U.S. Food and Drug Administration’s (FDA) newly released draft guidelines for the co-development of combination thera...